SCHEMBL4149016

SCHEMBL4149016

Cc1ccc2c(c1)nc(CCl)n2C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.50
HSD17B10 Q99714 1/20 0.50
RAB9A P51151 7/20 0.46
NPC1 O15118 6/20 0.46
MAPT P10636 2/20 0.46
ACSS2 Q9NR19 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.43
TLR8 Q9NR97 1/20 0.43
ALDH1A1 P00352 1/20 0.43
TP53 P04637 1/20 0.43
ALOX15 P16050 1/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
HDAC6 Q9UBN7 3/20 0.43
KMT2A Q03164 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
NLRP3 Q96P20 1/20 0.42
HDAC3 O15379 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13777230 0.86 RAB9A (0.49) KDM4ERAB9ANPC1MAPTACSS2
SCHEMBL12082560 0.84 KDM4E (0.51) KDM4EHSD17B10RAB9ANPC1MAPT
SCHEMBL13313014 0.83 KDM4E (0.57) KDM4EHSD17B10RAB9ANPC1MAPT
SCHEMBL4159853 0.83 KMT2A (0.49) KDM4ERAB9ANPC1MAPTSMN1; SMN2
SCHEMBL31569891 0.81 RAB9A (0.52) RAB9ANPC1MAPTSMN1; SMN2ALDH1A1
SCHEMBL103416 0.81 PIK3CD (0.47) RAB9ANPC1SMN1; SMN2ALDH1A1HDAC6
SCHEMBL10368883 0.80 NLRP3 (0.57) KDM4ERAB9ANPC1MAPTSMN1; SMN2
SCHEMBL11955229 0.80 KDM4E (0.48) KDM4EHSD17B10RAB9ANPC1MAPT
SCHEMBL14736501 0.80 MAPT (0.50) KDM4EHSD17B10RAB9ANPC1MAPT
Hydrochloric Acid SCHEMBL14736580 0.79 KDM4E (0.50) KDM4EHSD17B10RAB9ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116283911-A Preparation method of dabigatran etexilate 宿迁盛基医药科技有限公司 2023-06-23 CN disclosed
CN-116003384-A Synthesis method of dabigatran etexilate important intermediate 宿迁盛基医药科技有限公司 2023-04-25 CN disclosed
US-20090192169-A1 Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators ASTRAZENECA AB (SE) 2009-07-30 US disclosed
US-20090192169-A1 Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators ASTRAZENECA AB (SE) 2009-07-30 US disclosed
US-20090192169-A1 Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators ASTRAZENECA AB (SE) 2009-07-30 US disclosed
WO-2007115077-A2 BICYCLIC BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS ASTRAZENECA AB (SE) 2007-10-11 WO disclosed
EP-0012291-A1 Process for the preparation of benzimidazolyl benzofuranes BAYER AG (DE) 1980-06-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192169-A1 Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators GRM1, GRIN1, GRM2 KDM4E 3143/4885HSD17B10 3994/4885RAB9A 3021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.